CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ: FMI) today announced that results from a 24-month, multi-institution collaboration demonstrating the analytic validation of its cancer genomic profiling assay, FoundationOne™, were published in the current online edition of Nature Biotechnology.1 FoundationOne is a comprehensive, next-generation sequencing (NGS) based test used to characterize all classes of molecular alterations (base substitutions, short insertions and deletions (‘indels’), copy number alterations and select rearrangements) across 287 cancer-related genes from routine formalin-fixed, paraffin-embedded (FFPE) clinical specimens. The publication also describes clinical application of this assay across 2,221 consecutive patient cases.
Help employers find you! Check out all the jobs and post your resume.
